About DCN Diagnostics
DCN Diagnostics is a Healthcare company based in Carlsbad (United States) founded in 2004 by Brendan O Farrell and Michael L Surmanian. It operates as a lateral flow assay development and related services are offered. DCN Diagnostics has completed 3 acquisitions, including BioMed Diagnostics, IVD Vision and PortaScience. DCN Diagnostics offers products and services including Contract Assay Development, Contract Manufacturing, Custom Readers, and Clinical Research Services. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified. Its competitors include Abcam, Stem Cell Technologies, Teknova, Meridian Bioscience and BBI Solutions and 4 more; 5 of its 9 listed competitors have raised funding.
Company details
Founded in 2004 and based in Carlsbad, United States, DCN Diagnostics operates in the diagnostics sector, specializing in lateral flow, flow-through, and microfluidic assay formats. Training and commercialization services for lateral flow assay development are provided, alongside products such as starter kits, conjugation kits, reagents, and cassettes. Custom conjugations for proteins, particles, and small molecules are available, as well as consulting on assay development, manufacturing, regulation, and commercialization.
- InvestorsHHS
& 1 more
- Investments & AcquisitionsBioMed Diagnostics
& 2 more
Products & Services of DCN Diagnostics
DCN Diagnostics offers a comprehensive portfolio of products and services, including Contract Assay Development, Contract Manufacturing, Custom Readers, and Clinical Research Services.
Service for developing diagnostic assays and tests
Production of diagnostic consumables and devices
Design and creation of specialized diagnostic readers
Management of trials and data for diagnostics
Apps and channels of DCN Diagnostics
its YouTube channel DCN Diagnostics has 759 subscribers and 26 videos.
Videos from DCN Diagnostics
The most watched videos on DCN Diagnostics's YouTube channel, DCN Diagnostics (759 subscribers). Click a video to play it here.
More on DCN Diagnostics.
Funding Insights of DCN Diagnostics
- Total Rounds 3
- First Round $287,083
(Aug 2011)
- Investors Count 2
All 3 funding rounds of DCN Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | – | Private Equity Round | – | Martis Capital | – |
| Sep 2011 | $4.24M | Grant | – | – | |
| Aug 2011 | $287,083 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in DCN Diagnostics
DCN Diagnostics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS and Martis Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Martis Capital is focused on investing in healthcare transformation. | – | martiscapital.com | Washington, DC, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for DCN Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DCN Diagnostics
29 people are tracked at DCN Diagnostics (8 in leadership, 21 in team).
| Name | Role | Group |
|---|---|---|
Brendan O Farrell | Co-Founder | Leadership |
Michael L Surmanian | Co-Founder & Partner | Leadership |
Angela Rapattoni | VP Of Finance | Leadership |
Mitzi Rettinger | Chief Revenue Officer (cro) | Leadership |
Emily Friedland | Vice President Of Clinical Research | Leadership |
Francis Ko | Vice President, Manufacturing Operations | Leadership |
Patrick Vaughan | Chief Operating Officer | Leadership |
Cari Prosi | HR Director | Leadership |
Ashley Gorr | Project Manager | Team |
Winnie Tong | Program Manager | Team |
Veronika Atkinson | Principal Biostatistician | Team |
Jacqueline Olson | Marketing And Sales | Team |
Michelle Royce Cpa, Mba | Controller | Team |
Sarah B. | Sr. Clinical Trial Manager | Team |
Sophie Webster | Clinical Research Associate | Team |
Melanie Bader | Research Scientist Iii/training Specialist | Team |
Jerry Lin | Research Scientist | Team |
Francis Ronald Go | Research Scientist I | Team |
John Scott | Senior Scientist | Team |
Helen V Hsieh | Senior Scientist | Team |
9 more people are available in the full profile.
Complete people profiles for DCN Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DCN Diagnostics
DCN Diagnostics has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include BioMed Diagnostics, IVD Vision and PortaScience.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufacturer of microbiology diagnostic devices | biomeddiagnostics.com | White, United States | 2001 | Apr 2022 | •••• | |
Analytical instruments for chemical and biochemical assays are developed. | ivdvision.com | Carlsbad, United States | 2014 | Jun 2021 | •••• | |
Develops rapid diagnostic assays and platforms | portascience.com | Moorestown, United States | 1999 | Jun 2021 | •••• |
Complete acquisition details for DCN Diagnostics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of DCN Diagnostics
6 dated milestones of DCN Diagnostics across 18 years, from founding to its latest funding, stage changes and deals.
- Founded DCN Diagnostics is founded.
- Funding First funding round of $287K.
- Funding Latest funding round, Private Equity Round,.
- Acquisition Acquires PortaScience.
- Acquisition Acquires IVD Vision.
- Acquisition Acquires BioMed Diagnostics.
Competitors of DCN Diagnostics
DCN Diagnostics has 9 listed competitors in our database, 5 of them funded. They include Abcam, Stem Cell Technologies, Teknova, Meridian Bioscience and BBI Solutions, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| bbisolutions.com | 1986 | Crumlin, United Kingdom | – | 301 | Kits and reagents are developed for life science research applications. | |
| sangon.com | 2003 | Shanghai, China | $300M | – | Research services, reagents, and kits for biotech applications are provided. | |
| biochain.com | 1994 | Hayward, United States | $7.34M | 24 | Provider of products and services for clinical diagnosis, genomics, and proteomics | |
| caymanchem.com | 1980 | Ann Arbor, United States | – | 309 | Bioreagents and assay kits are developed, with preclinical services provided. | |
| biolamina.com | 2008 | Sundbyberg, Sweden | $18.25M | – | Recombinant laminins are produced for stem cell culture matrices. |
Detailed competitors of DCN Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DCN Diagnostics
The website of DCN Diagnostics (dcndx.com) receives about 8.6K visits a month.
- Monthly visits8.6K
▼ 32.2% vs previous month
Websites whose visitors overlap most with DCN Diagnostics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cellgs.com | 100% | 44.1K | #817,790 | View details | |
| gmotesting.com | 95% | – | #12,207,505 | View details | |
bioresearchonline.com | bioresearchonline.com | 82% | – | – | – |
metachem.co.uk | metachem.co.uk | 81% | – | – | – |
| biogenuix.com | 81% | 1.7K | #8,523,738 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for DCN Diagnostics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as DCN Diagnostics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dcn Diagnostics
Complete news archive for DCN Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DCN Diagnostics
DCN Diagnostics was founded in 2004 and raised its 1st funding round 7 years after it was founded.
DCN Diagnostics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Founded in 2004 and based in Carlsbad, United States, DCN Diagnostics operates in the diagnostics sector, specializing in lateral flow, flow-through, and microfluidic assay formats. Training and commercialization services for lateral flow assay development are provided, alongside products such as starter kits, conjugation kits, reagents, and cassettes. Custom conjugations for proteins, particles, and small molecules are available, as well as consulting on assay development, manufacturing, regulation, and commercialization.
DCN Diagnostics's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.
DCN Diagnostics offers Contract Assay Development, Contract Manufacturing, Custom Readers, and Clinical Research Services.
DCN Diagnostics has made 3 acquisitions, including BioMed Diagnostics, IVD Vision, and PortaScience.
DCN Diagnostics has 2 investors. Key investors include HHS, and Martis Capital.